[1]甘建国,肖春雨,甘山花,等.β2受体激动剂联合抗生素在慢性阻塞性肺病急性发作期的临床效果及安全性分析[J].医学信息,2024,37(23):109-112.[doi:10.3969/j.issn.1006-1959.2024.23.026]
　GAN Jianguo,XIAO Chunyu,GAN Shanhua,et al.Clinical Effect and Safety Analysis of β2 Receptor Agonist Combined with Antibiotics in Acute Exacerbation of Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2024,37(23):109-112.[doi:10.3969/j.issn.1006-1959.2024.23.026]
点击复制

β2受体激动剂联合抗生素在慢性阻塞性肺病急性发作期的临床效果及安全性分析()

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年23期
页码:
109-112
栏目:
药物与临床
出版日期:
2024-12-01

文章信息/Info

Title:
Clinical Effect and Safety Analysis of β2 Receptor Agonist Combined with Antibiotics in Acute Exacerbation of Chronic Obstructive Pulmonary Disease
文章编号:
1006-1959（2024）23-0109-04
作者:
甘建国; 肖春雨; 甘山花; 江 涛
崇义县人民医院内三科，江西 崇义 341300
Author(s):
GAN Jianguo; XIAO Chunyu; GAN Shanhua; JIANG Tao
The Third Department of Internal Medicine,Chongyi County People′s Hospital,Chongyi 341300,Jiangxi,China
关键词:
β2受体激动剂; 抗生素; 慢性阻塞性肺病; 急性发作期; 安全性
Keywords:
β2 receptor agonist; Antibiotics; Chronic obstructive pulmonary disease; Acute exacerbation; Safety
分类号:
R563.9
DOI:
10.3969/j.issn.1006-1959.2024.23.026
文献标志码:
A
摘要:
目的 观察β2受体激动剂联合抗生素在慢性阻塞性肺病急性发作期的临床效果及安全性。方法 选取2022年1月-2023年3月我院收治的80例慢性阻塞性肺病急性发作期患者为研究对象，采用随机数字表法分为常规组和研究组，各40例。常规组采用抗生素治疗，研究组在常规组基础上联合β2受体激动剂治疗，比较两组临床效果、6 min步行距离、呼吸困难分级评分、肺功能指标[1秒用力呼气容积（FEV1）、第一秒用力呼气容积占用力肺活量的比值（FEV1/FVC）]、血气指标[动脉血二氧化碳分压（PaCO2）、动脉血氧分压（PaO2）]，以及不良反应发生率。结果 研究组治疗总有效率为95.00%，高于常规组的87.50%（P＜0.05）；研究组6 min步行距离、呼吸困难评分、FEV1、FEV1/FVC、PaO2、PaCO2均优于常规组（P＜0.05）；研究组不良反应发生率为7.50%，与常规组的10.00%比较，差异无统计学意义（P＞0.05）。结论 β2受体激动剂联合抗生素在慢性阻塞性肺病急性发作期具有确切的效果，可降低患者呼吸困难评分，提高治疗有效率，增大6 min步行距离，改善肺功能和血气指标，且不增加临床不良反应发生率，值得临床加以应用。
Abstract:
Objective To observe the clinical effect and safety of β2 receptor agonist combined with antibiotics in acute exacerbation of chronic obstructive pulmonary disease.Methods During January, 2022 and March, 2023, 80 patients with acute exacerbation of chronic obstructive pulmonary disease admitted to our hospital were collected, and grouped by random number table method, while 40 patients were enrolled in the routine group and 40 patients were enrolled in the research group. Antibiotics was used for treatment in the routine group, while the research group was addedβ2 receptor agonist on the basis of the method which was carry out in the routine group.Results In comparison with the routine group, the research group was observed to have a higher total effective rate (P<0.05). Compared with the patients in the routine group after the treatment, 6-minute walking distance, dyspnea grading scores, and FEV1, FEV1/FVC, PaO2, PaCO2 level in the research group were significantly superior to the routine group (P<0.05). The incidence of adverse reactions in the research group was 7.50%, which was compared with 10.00% in the routine group, the difference was not statistically significant(P>0.05).Conclusion β2 receptor agonist combined with antibiotics has a definite effect in the acute exacerbation of chronic obstructive pulmonary disease, which can reduce the dyspnea score of patients, improve the treatment efficiency, increase the 6-minute walking distance, improve lung function and blood gas index, and do not increase the incidence of clinical adverse reactions. It is worthy of clinical application.

参考文献/References:

[1]张海涛,张映铭,王彩英,等.盐酸氨溴索联合N-乙酰半胱氨酸对慢性阻塞性肺病患者血清胸腺基质淋巴生成素和嗜酸粒细胞阳离子蛋白的影响[J].海军医学杂志,2017,38(6):513-516.[2]顾联斌,朱怡.乙酰半胱氨酸联合氨溴索治疗老年慢性阻塞性肺病急性发作期的临床研究[J].现代药物与临床,2017,32(4):636-639.[3]张石革,陈瑞红,梁建华.第四代喹诺酮类药物的合理应用[J].首都医药,2003,10(4):34-37.[4]胡丽娟,朱亚龙,廖军.慢性阻塞性肺疾病急性发作期合并糖尿病患者甲状腺激素水平变化及与预后的关系[J].基层医学论坛,2023,8(1):11-15.[5]井泉.乙酰半胱氨酸联合氨溴索治疗老年慢性阻塞性肺病急性发作期的临床价值分析[J].医学理论与实践,2019,25(4):72-75.[6]黄如坤,蔡木泾,林天植.糖皮质激素应用于慢性阻塞性肺病急性加重期治疗效果观察[J].黑龙江医药,2019,25(12):90-93.[7]夏婉飞,黄国华,古辉,等.噻托溴铵/奥达特罗治疗C、D组慢性阻塞性肺疾病稳定期患者的效果[J].广州医药,2023,20(4):28-31.[8]蒋一雅,仇铁峰,庄志方.胸腺法新辅助治疗对老年慢性阻塞性肺病急性发作患者血气分析及免疫功能的影响[J].山西医药杂志,2017,25(8):94-96.[9]李志强.布地奈德福莫特罗、沙美特罗替卡松吸入治疗缓解期慢性阻塞性肺病的效果、安全性及生存质量对比研究[J].贵州医药,2019,28(4):176-180.[10]曹月琴.稳定期长期口服大环内酯类抗生素在预防慢性阻塞性肺病急性加重中的作用[D].南京:南京医科大学,2019.[11]吴永欣,陈飞,孙慧敏,等.半夏厚朴汤联合沙美特罗替卡松辅治慢性阻塞性肺疾病急性发作期临床观察[J].实用中医药杂志,2023,25(7):11-15.[12]崔涛,马姣,石芳,等.不同剂量阿奇霉素维持治疗稳定期COPD患者的临床疗效[J].中国老年学杂志,2022,10(6):155-157.[13]亢旭锋.盐酸莫西沙星治疗慢性阻塞性肺疾病急性发作的疗效与不良反应分析[J].基层医学论坛,2021,10(1):61-64.[14]王伟,李萍.莫西沙星与细菌溶解产物胶囊联用对慢性阻塞性肺疾病急性发作的疗效及其对免疫球蛋白水平改善的影响[J].抗感染药学,2018,25(12):107-110.[15]杨佳.应激激素对慢性阻塞性肺疾病患者急性加重风险的影响[D].南宁:广西医科大学,2017.[16]彭丽萍,吕晓红,于振香.沙美特罗替卡松联合白三烯受体拮抗剂治疗咳嗽变异性哮喘临床观察[J].吉林大学学报(医学版),2008,34(2):325-327.[17]章哲,张文喜,赵蓓.沙美特罗替卡松气雾剂对小儿哮喘发作期血清IgE、NO及SOD水平影响研究[J].中国生化药物杂志,2016,36(3):61-63.[18]查红群,毛娉婷,沈冬梅.不同抗生素在治疗慢性阻塞性肺病急性加重期的疗效分析[J].江西医药,2019,20(11):114-117.[19]王宝君.乙酰半胱氨酸溶液雾化吸入联合布地奈德福莫特罗粉吸入剂对慢性阻塞性肺疾病急性加重期患者肺功能及血气指标的影响[J].中国药物与临床,2021,21(3):460-461.[20]陈先华,刘引,杨陵,等.硫酸庆大霉素联合布地奈德溶液雾化吸入治疗急性支气管炎107例疗效观察[J].中华肺部疾病杂志(电子版),2020,13(1):69-71.[21]付东伟,崔吉宏,涂钰林.沙美特罗替卡松与氨茶碱联合治疗对慢性阻塞性肺病急性加重期疗效和氧化应激的影响[J].中国现代医学杂志,2017,21(10):112-115.[22]邓敦莹.特布他林联合布地奈德雾化吸入治疗慢性阻塞性肺病急性发作的临床效果观察[J].中国医药科学,2017,15(3):44-47.[23]王超,陈晓君,宋晓莉,等.莫西沙星左氧氟沙星序贯给药对老年重症慢性阻塞性肺疾病急性加重期患者呼吸功能微炎症的影响研究[J].河北医学,2023,30(4):96-98.[24]马菲菲,史亮.莫西沙星治疗COPD合并呼衰对患者肺功能氧代谢及血清CRPCKLDHNBC水平的影响[J].河北医学,2021,30(6):71-74.

相似文献/References:

[1]吴君华,吴友茹,李 丹.血清降钙素原在AECOPD抗感染治疗中的应用价值研究[J].医学信息,2018,31(02):74.[doi:10.3969/j.issn.1006-1959.2018.02.025]
　WU Jun-hua,WU You-ru,LI Dan.Study on the Application Value of Serum Calcitonin in the Anti Infection Treatment of AECOPD[J].Journal of Medical Information,2018,31(23):74.[doi:10.3969/j.issn.1006-1959.2018.02.025]
[2]王晋蜀,黄梦雅,赵明丹,等.泌尿生殖道支原体感染检测、鉴定及耐药性分析[J].医学信息,2018,31(16):98.[doi:10.3969/j.issn.1006-1959.2018.16.029]
　WANG Jin-shu,HUANG Meng-ya,ZHAO Ming-dan,et al.Detection,Identification and Drug Resistance Analysis of Urogenital Mycoplasma Infection[J].Journal of Medical Information,2018,31(23):98.[doi:10.3969/j.issn.1006-1959.2018.16.029]
[3]于文清.下呼吸道感染病原菌分布及耐药性分析[J].医学信息,2018,31(24):74.[doi:10.3969/j.issn.1006-1959.2018.24.019]
　YU Wen-qing.Analysis of Distribution and Drug Resistance of Pathogenic Bacteria in Lower Respiratory Tract Infection[J].Journal of Medical Information,2018,31(23):74.[doi:10.3969/j.issn.1006-1959.2018.24.019]
[4]张佳佳,李 庆,王 同.中性粒细胞CD64指数指导慢性阻塞性肺疾病急性加重期抗生素应用的探讨[J].医学信息,2019,32(07):78.[doi:10.3969/j.issn.1006-1959.2019.07.023]
　ZHANG Jia-jia,LI Qing,WANG Tong.The Application of Neutrophil CD64 Index in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2019,32(23):78.[doi:10.3969/j.issn.1006-1959.2019.07.023]
[5]叶志萍,宋 娇,荣 丹.抗宫炎胶囊联合抗生素对慢性宫颈炎患者的疗效及对T淋巴细胞亚群水平的影响[J].医学信息,2022,35(15):95.[doi:10.3969/j.issn.1006-1959.2022.15.021]
　YE Zhi-ping,SONG Jiao,RONG Dan.Effect of Kanggongyan Capsule Combined with Antibiotics on T Lymphocyte Subsets in Patients with Chronic Cervicitis[J].Journal of Medical Information,2022,35(23):95.[doi:10.3969/j.issn.1006-1959.2022.15.021]
[6]宣恒报,成玉春,杨士军.医院感染的耐药菌分布特点与药物应用[J].医学信息,2019,32(22):114.[doi:10.3969/j.issn.1006-1959.2019.22.037]
　XUAN Heng-bao,CHENG Yu-chun,YANG Shi-jun.Distribution Characteristics and Drug Application of Drug-resistant Bacteria in Nosocomial Infection[J].Journal of Medical Information,2019,32(23):114.[doi:10.3969/j.issn.1006-1959.2019.22.037]
[7]赵 培.抗生素降阶梯方案治疗小儿重症肺炎的有效性与安全性分析[J].医学信息,2020,33(03):146.[doi:10.3969/j.issn.1006-1959.2020.03.047]
　ZHAO Pei.Effect of Antibiotic Step-down Protocol on Children with Severe Pneumonia[J].Journal of Medical Information,2020,33(23):146.[doi:10.3969/j.issn.1006-1959.2020.03.047]
[8]杨昌妮,李 宇,李晓芳,等.老年社区获得性肺炎诊治报道1例并文献复习[J].医学信息,2020,33(17):188.[doi:10.3969/j.issn.1006-1959.2020.17.059]
[9]邓智心,袁 莹,邹志玲,等.不孕症患者慢性子宫内膜炎的诊疗[J].医学信息,2021,34(11):31.[doi:10.3969/j.issn.1006-1959.2021.11.010]
　DENG Zhi-xin,YUAN Ying,ZOU Zhi-ling,et al.Diagnosis and Treatment of Chronic Endometritis in Infertility Patients[J].Journal of Medical Information,2021,34(23):31.[doi:10.3969/j.issn.1006-1959.2021.11.010]
[10]周 瑞,张雪芬,张 宁,等.抗生素对早产儿肠道菌群影响的研究[J].医学信息,2023,36(03):177.[doi:10.3969/j.issn.1006-1959.2023.03.039]
　ZHOU Rui,ZHANG Xue-fen,ZHANG Ning,et al.Effect of Antibiotics on Intestinal Microflora in Premature Infants[J].Journal of Medical Information,2023,36(23):177.[doi:10.3969/j.issn.1006-1959.2023.03.039]

更新日期/Last Update: 1900-01-01